Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,069 public trials 582 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mass General/North Shore Cancer Center Danvers, Massachusetts, United States
  • Newton-Wellesley Hospital Newton, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham, Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University Atlanta, Georgia, United States
View all 40 locations
View Trial Details
Active, Not Recruiting

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • University of Florida Gainesville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Loyola University Medical Center Chicago, Illinois, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

NCT05013190

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Anhui Cancer Hospital Hefei, Anhui, China
  • Beijing Chao-Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
  • Beijing Jishuitan Hospital Beijing, Beijing Municipality, China
  • Henan Province People Hospital Zhengzhou, Henan, China
View Trial Details
Active, Not Recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria, Italy
  • A.O.U. Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
  • Ospedale C. e G. Mazzoni - U.O.C. di Ematologia Ascoli Piceno, Italy
  • AOU Policlinico Consorziale - U.O. Ematologia con Trapianto Bari, Italy
View all 28 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Medstar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • University of Miami Miami, Florida, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05704049

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Investigational Site Number : 0360002 Wollongong, New South Wales, Australia
  • Investigational Site Number : 0360001 Melbourne, Victoria, Australia
  • Hospital Mae de Deus Site Number : 0760002 Porto Alegre, Rio Grande do Sul, Brazil
  • Clinica São Germano- Site Number : 0760003 São Paulo, Brazil
View all 23 locations
View Trial Details

Related conditions